KR20240065283A - Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법 - Google Patents

Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법 Download PDF

Info

Publication number
KR20240065283A
KR20240065283A KR1020247012854A KR20247012854A KR20240065283A KR 20240065283 A KR20240065283 A KR 20240065283A KR 1020247012854 A KR1020247012854 A KR 1020247012854A KR 20247012854 A KR20247012854 A KR 20247012854A KR 20240065283 A KR20240065283 A KR 20240065283A
Authority
KR
South Korea
Prior art keywords
hair follicles
tyk2
formula
days
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247012854A
Other languages
English (en)
Korean (ko)
Inventor
이안 맥쿼리 캐트렛
진 김
마르타 베르톨리니
야닌 에델캄프
토마스 로우일레
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20240065283A publication Critical patent/KR20240065283A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
KR1020247012854A 2021-09-23 2022-09-22 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법 Pending KR20240065283A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163247672P 2021-09-23 2021-09-23
US63/247,672 2021-09-23
PCT/US2022/044346 WO2023049241A1 (en) 2021-09-23 2022-09-22 Methods of treating hair-loss disorders with tyk2 inhibitors

Publications (1)

Publication Number Publication Date
KR20240065283A true KR20240065283A (ko) 2024-05-14

Family

ID=83899658

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247012854A Pending KR20240065283A (ko) 2021-09-23 2022-09-22 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법

Country Status (10)

Country Link
US (1) US20240390372A1 (https=)
EP (1) EP4404930A1 (https=)
JP (1) JP2024533700A (https=)
KR (1) KR20240065283A (https=)
CN (2) CN118251222A (https=)
AU (1) AU2022350509A1 (https=)
CA (1) CA3232812A1 (https=)
IL (1) IL311624A (https=)
MX (1) MX2024003510A (https=)
WO (1) WO2023049241A1 (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
TWI582077B (zh) * 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
TW202515876A (zh) * 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
US20230093099A1 (en) * 2019-04-02 2023-03-23 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
US12570637B2 (en) 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
JP7812785B2 (ja) 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
AU2021205465A1 (en) * 2020-01-06 2022-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN111704617B (zh) * 2020-06-15 2022-08-23 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN112142675B (zh) * 2020-10-09 2021-11-30 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途

Also Published As

Publication number Publication date
CA3232812A1 (en) 2023-03-30
JP2024533700A (ja) 2024-09-12
IL311624A (en) 2024-05-01
EP4404930A1 (en) 2024-07-31
US20240390372A1 (en) 2024-11-28
AU2022350509A1 (en) 2024-04-04
MX2024003510A (es) 2024-04-09
WO2023049241A1 (en) 2023-03-30
CN118251222A (zh) 2024-06-25
CN119345364A (zh) 2025-01-24

Similar Documents

Publication Publication Date Title
Zhuang et al. Induction of M2 macrophages prevents bone loss in murine periodontitis models
Alvarado et al. Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study
Munera-Campos et al. Innovation in atopic dermatitis: from pathogenesis to treatment
Milenkovic et al. P2Y receptor-mediated stimulation of Muller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation
Weinblatt et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve‐week, randomized, placebo‐controlled trial
Pellegatta et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
JP6054889B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
van Steensel et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves’ ophthalmopathy
Swamynathan et al. Klf4 regulates the expression of Slurp1, which functions as an immunomodulatory peptide in the mouse cornea
Lin et al. Heme oxygenase‐1 directly binds STAT 3 to control the generation of pathogenic Th17 cells during neutrophilic airway inflammation
Rottlaender et al. Neuroprotective role of fibroblast growth factor‐2 in experimental autoimmune encephalomyelitis
Alves et al. Quinacrine suppresses tumor necrosis factor-α and IFN-α in dermatomyositis and cutaneous lupus erythematosus
Huang et al. M2‐like macrophages polarized by Foxp3− Treg‐of‐B cells ameliorate imiquimod‐induced psoriasis
Ji et al. Normalization of non‐canonical Wnt signalings does not compromise blood‐brain barrier protection conferred by upregulating endothelial Wnt/β‐catenin signaling following ischemic stroke
Lai et al. Novel approach to alleviate lupus nephritis: targeting the NLRP3 inflammasome in CD8+ CD69+ CD103+ TRM cells
Sanchez et al. The antiretroviral agent nelfinavir mesylate: a potential therapy for systemic sclerosis
Pinget et al. Immune modulation of monocytes dampens the IL-17+ γδ T cell response and associated psoriasis pathology in mice
Grando Muscarinic receptor agonists and antagonists: effects on keratinocyte functions
Ni et al. Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study
Zhang et al. CCN1 upregulates IL‐36 via AKT/NF‐κB and ERK/CEBP β‐mediated signaling pathways in psoriasis‐like models
Németh et al. Neutrophil-specific syk expression is crucial for skin disease in experimental epidermolysis bullosa acquisita
Lee et al. Interleukin 15 activates Akt to protect astrocytes from oxygen glucose deprivation-induced cell death
US20240390372A1 (en) Methods of treating hair-loss disorders with tyk2 inhibitors
Liu et al. Exogenous ephrin-A3 reverses loss of vaginal epithelial barrier protection in progestin-treated mice
US20170360888A1 (en) Methods for treating inflammatory arthritis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000